Journal
ANNALES D ENDOCRINOLOGIE
Volume 79, Issue 5, Pages 550-554Publisher
MASSON EDITEUR
DOI: 10.1016/j.ando.2018.07.004
Keywords
-
Categories
Ask authors/readers for more resources
As well as tyrosine kinase and mTOR inhibitors, new anticancer therapies make use of antibodies targeting tyrosine kinase receptors or blocking anti-tumor immune response checkpoints. These are always monoclonal; in their international non-proprietary names, the origin is prefixed to -mab: e.g., mouse antibodies end in o-mab, chimeric antibodies in xi-mab, humanized antibodies in zu-mab and human antibodies in u-mab. When the analytic principle of the assay involves a murine monoclonal antibody and the therapeutic antibody contains a murine sequence, analytic interference is to be feared if the patient develops antibodies against the therapeutic antibody. The interfering heterophilic antibody may be a HAMA (anti-mouse), a HACA (anti-chimeric) or a HAHA (anti-humanized-antibody). In immunoassay for patients under immunotherapy, it is therefore recommended to check the type of therapeutic antibody: if it is liable to contain murine sequences, heterophilic antibodies should be screened for and neutralized. (C) 2018 Published by Elsevier Masson SAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available